US20100311967A1 - Production of bepromoline - Google Patents
Production of bepromoline Download PDFInfo
- Publication number
- US20100311967A1 US20100311967A1 US12/858,273 US85827310A US2010311967A1 US 20100311967 A1 US20100311967 A1 US 20100311967A1 US 85827310 A US85827310 A US 85827310A US 2010311967 A1 US2010311967 A1 US 2010311967A1
- Authority
- US
- United States
- Prior art keywords
- hcl
- formula
- compound
- bepromoline
- amorolfine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 67
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 29
- 230000008569 process Effects 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract 4
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 10
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 10
- CRNIHJHMEQZAAS-UHFFFAOYSA-N tert-amyl chloride Chemical compound CCC(C)(C)Cl CRNIHJHMEQZAAS-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- 229960003204 amorolfine Drugs 0.000 description 52
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 48
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 35
- 239000002585 base Substances 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- MQHLMHIZUIDKOO-AYHJJNSGSA-N amorolfine Chemical compound C1=CC(C(C)(C)CC)=CC=C1CC(C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-AYHJJNSGSA-N 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- GTXJQSYVXLUOCW-GOOCMWNKSA-N CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.Cl Chemical compound CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.Cl GTXJQSYVXLUOCW-GOOCMWNKSA-N 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- RYAUSSKQMZRMAI-ALOPSCKCSA-N (2S,6R)-4-[3-(4-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine Chemical compound C=1C=C(C(C)(C)C)C=CC=1CC(C)CN1C[C@H](C)O[C@H](C)C1 RYAUSSKQMZRMAI-ALOPSCKCSA-N 0.000 description 11
- 238000004821 distillation Methods 0.000 description 11
- 239000005778 Fenpropimorph Substances 0.000 description 10
- VLUMOWNVWOXZAU-VQHVLOKHSA-N (e)-2-methyl-3-phenylprop-2-enal Chemical compound O=CC(/C)=C/C1=CC=CC=C1 VLUMOWNVWOXZAU-VQHVLOKHSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- HNVIQLPOGUDBSU-OLQVQODUSA-N (2s,6r)-2,6-dimethylmorpholine Chemical compound C[C@H]1CNC[C@@H](C)O1 HNVIQLPOGUDBSU-OLQVQODUSA-N 0.000 description 7
- 238000005984 hydrogenation reaction Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000001496 (E)-2-methyl-3-phenylprop-2-enal Substances 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000003547 Friedel-Crafts alkylation reaction Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- HNVIQLPOGUDBSU-UHFFFAOYSA-N 2,6-dimethylmorpholine Chemical compound CC1CNCC(C)O1 HNVIQLPOGUDBSU-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- YZSCPLGKKMSBMV-UHFFFAOYSA-N 5-fluoro-4-(8-fluoro-4-propan-2-yl-2,3-dihydro-1,4-benzoxazin-6-yl)-N-[5-(1-methylpiperidin-4-yl)pyridin-2-yl]pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)C1CCN(CC1)C)C1=CC2=C(OCCN2C(C)C)C(=C1)F YZSCPLGKKMSBMV-UHFFFAOYSA-N 0.000 description 1
- XFCLNDHSNARNQO-WSFBTNFHSA-N C/C(C=O)=C\C1=CC=CC=C1.CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.C[C@H]1CNC[C@@H](C)O1.Cl Chemical compound C/C(C=O)=C\C1=CC=CC=C1.CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.C[C@H]1CNC[C@@H](C)O1.Cl XFCLNDHSNARNQO-WSFBTNFHSA-N 0.000 description 1
- ZTETXXWAIGCYAO-AOCIYXACSA-N CC(CC1=CC=CC=C1)CN1C[C@@H](C)O[C@H](C)C1.CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@@H](C)C1 Chemical compound CC(CC1=CC=CC=C1)CN1C[C@@H](C)O[C@H](C)C1.CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@@H](C)C1 ZTETXXWAIGCYAO-AOCIYXACSA-N 0.000 description 1
- ORRCDGQFZKVITK-GGSZWWIISA-N CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.Cl.Cl Chemical compound CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.Cl.Cl ORRCDGQFZKVITK-GGSZWWIISA-N 0.000 description 1
- ZEWKPRDCQFMUSI-CUVWUJFMSA-N CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.CCC(C)(C)Cl.Cl Chemical compound CC(CC1=CC=CC=C1)CN1C[C@H](C)O[C@H](C)C1.CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.CCC(C)(C)Cl.Cl ZEWKPRDCQFMUSI-CUVWUJFMSA-N 0.000 description 1
- BZMTVYONCSRSMG-OAQAYXNDSA-N CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1 Chemical compound CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1 BZMTVYONCSRSMG-OAQAYXNDSA-N 0.000 description 1
- YUZSAZBEGBJWDU-QTSMYMJXSA-N CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.CCO.Cl.Cl Chemical compound CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1.CCO.Cl.Cl YUZSAZBEGBJWDU-QTSMYMJXSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- CMQCNTNASCDNGR-UHFFFAOYSA-N toluene;hydrate Chemical compound O.CC1=CC=CC=C1 CMQCNTNASCDNGR-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/023—Preparation; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
Definitions
- the present invention relates to an improved process of producing bepromoline hydrochloride (bepromoline HCl), which is an intermediate used in the production of Amorolfine (AMF) hydrochloride (Amorolfine HCl).
- Amorolfine HCl is an active pharmaceutical ingredient (API) formulated into topical anti-mycotic (anti-fungal) compositions.
- the suggested catalysts are those generally employed for hydrogenation, with specific mention of platinum, palladium, palladiumcarbon or Raney nickel catalysts. No indication is made of the pH of the hydrogenation conditions.
- Need continues to exist for improved processes for the production of Amorolfine salts, for example Amorolfine HCl, notably through an improvement in the production of its intermediates, such as bepromoline or a salt of bepromoline as, for example, bepromoline HCl.
- bepromoline base refers to the compound of formula (Ia)
- bepromoline HCl refers to the compound of formula (Ib)
- Amorolfine HCl refers to the compound of formula (II):
- the present invention relates to an improved process for producing bepromoline HCl, an intermediate in the production of AMF HCl.
- This acetic acid addition (step (ii)) is for the reduction of the C ⁇ N double bond under hydrogen pressure.
- step (i) is conducted under basic conditions and acetic acid added once the consumption of hydrogen gas has ceased.
- step (i) The reduction under hydrogen pressure of the C ⁇ C double bond is better conducted under basic conditions (step (i)), and once the consumption of hydrogen gas has ceased, the reduction under hydrogen pressure of the C ⁇ N double bond is better conducted under acetic conditions (step (ii)).
- a preferred process according to the invention is a process of preparing bepromoline base, which is a compound of formula (Ia):
- step (i) is conducted under basic conditions, and (ii), once the consumption of hydrogen gas has ceased, acetic acid is added.
- the palladium catalyst comprises palladium precipitated onto carbon.
- the basic conditions are provided by potassium hydroxide, although other alkalis can also be used. It has been found that the inclusion of 1.5 to 2.0 mol % potassium hydroxide, typically about 1.8 mol % potassium hydroxide, is sufficient.
- said process comprising a process described above for the first embodiment of the invention followed by the following step: (iii) contacting the compound of formula (Ia) with toluene and HCl gas to produce a compound of formula (Ib).
- the toluene and HCl gas are added at a temperature of up to 50° C.
- the process of preparing a compound of formula (Ib) includes one or more of the following steps:
- step (a) entails:
- the solubilization of the compound of formula (Ia) in toluene followed by acidification with hydrochloric acid are particularly useful, because this step avoids distillation of the compound of formula (Ia), which is long-time consuming.
- the solid hydrochloride salt of formula (Ib) obtained in toluene is easier to handle than the liquid compound of formula (Ia) and can be directly employed in the following reaction.
- process comprising a process described above for any of the first, or second embodiment of the present invention.
- bepromoline HCl (compound (Ib)) can be contacted with, for example, FeCl 3 , and then added to 2-chloro-2-methylbutane.
- bepromoline base (compound (Ia)
- bepromoline HCl can be converted to bepromoline HCl by a salification step, and then submitted to the same reactions as herein above described (contact with for example FeCl 3 , and then addition to 2-chloro-2-methylbutane).
- the process of the third embodiment further includes the step of reacting a compound of formula (Ib) with 2-chloro-2-methylbutane in the presence of FeCl 3 as Friedel-Crafts catalyst.
- the Friedel-Crafts catalyst will usually be embodiment in a suitable solvent, for example dichloromethane (DCM).
- a suitable solvent for example dichloromethane (DCM).
- the compound of formula (Ib) is contacted with the Friedel-Crafts catalyst at room temperature.
- the 2-chloro-2-methylbutane is added to the compound of formula (Ib) at a temperature of ⁇ 40° C. to ⁇ 60° C., for example ⁇ 50° C.
- a process for preparing a compound of formula (II) comprising the process of any of first, second, or third embodiments of the invention.
- the process for preparing a compound of formula (II) further comprises the step of crystallizing AMF HCl from addition of HCl to a solution of AMF base in ethanol.
- the present invention also features the compound of formula (Ia) (bepromoline base) or to compound of formula (Ib) (bepromoline HCl), each of these compounds having a purity degree superior or equal to 99.5%.
- a mixture of one part of ⁇ -methyl-cinnamaldehyde to one part of cis-2,6-dimethyl-morpholine (DMM) is hydrogenated in methanol in the presence of catalytic amount of palladium on carbon, optionally under basic conditions until the uptake of H 2 gas ceases, this indicating completion of the reduction of the C ⁇ C double bond.
- Acetic acid is then added for the reduction of the C ⁇ N double bond under hydrogen pressure; the C ⁇ N double bond is formed between the aldehyde and the amino moiety of the two reactants, ⁇ -methyl-cinnamaldehyde and DMM, respectively.
- the catalyst is then filtered off and the methanol is removed by distillation.
- Toluene is added and the inorganic components are removed by washing with water.
- Toluene and unreacted DMM are distilled off.
- fresh toluene and HCl gas are added and the pH is adjusted to 3-4.
- the bepromoline HCl is centrifuged and dried.
- Methanol may be substituted by toluene to avoid the later solvent exchange step.
- 40° C. is the optimum temperature for both hydrogenation steps.
- the temperature may typically be set at no more than 45° C., preferably between 30° C. and 45° C.
- the reduction for the C ⁇ N double bond formed between the aldehyde and the amino function of the two components is conducted under hydrogen pressure in acidic conditions after the addition of acetic acid.
- a molar ratio of acetic acid to KOH is around 1.3 ( ⁇ 10%).
- the acetic acid is typically added at a temperature range of between 40° C. to 45° C., and no more than 45° C.
- the toluene is advantageously added to facilitate the phase separations and the distillation step of the unreacted DMM, thus improving the purity of bepromoline.
- the purity of the bepromoline HCl (cis isomer) is superior or equal to 99.5%.
- the product is stable up to 150° C.
- a reactor was charged with 146 kg a-methyl-cinnamaldehyde, 115 kg cis-2,6-dimethyl-morpholine, 2.1 kg 50% KOH, 278 kg methanol and 5.8 kg of a palladium/carbon catalyst and then filled with hydrogen at 15-25° C.
- the hydrogenation was then conducted at a pressure of ⁇ 2 bar and 35-45° C. until H 2 consumption ceased.
- reaction mixture was filtered and the catalyst washed with methanol and water.
- the solvents were distilled off at a temperature of up to 95° C. under vacuum.
- the reactor was charged with 904 kg toluene and 33 kg HCl gas at a temperature of up to 50° C. Then the pH was adjusted to 3-4. The reaction mixture was cooled and then stored sufficiently to reached complete crystallization.
- the mixture was centrifuged and washed with cold (0-5° C.) toluene. A second crop of Bepromoline HCl was isolated from the mother liquor.
- the process yielded 287 kg wet bepromoline HCl, which was then dried at 60° C. under vacuum. After drying, the first crop of Bepromoline HCl was 227 kg and the second 18 kg. This corresponds to a yield of 87% (80% for the first crop Bepromoline HCl and 7% for the second crop).
- reaction mixture is poured onto an ice-water mixture.
- the organic phase is separated and washed with acidic water, and then with sodium phosphate solution and with sodium hydroxide solution. After a stripping with toluene, extractions with water are performed. The solvent is then removed. Then the residue is distilled.
- a suitable molar ratio of FeCl 3 to bepromoline is 1:2 to 1:5 equivalents of catalyst. 1.3 equivalents of FeCl 3 are preferred.
- the reaction is conducted at low temperature, preferably ⁇ 50° C. (see Table 2):
- FPM Fenpropimorph
- FPM Fenpropimorph
- the Amorolfine HCl (which is in the DCM) is converted to the free base during these extractions. Phosphate was used to remove traces of Fe.
- the reactor was charged with 212 kg FeCl 3 and 757 kg DCM. 284 kg bepromoline HCl in 946 kg DCM were added to the reactor at 20-30° C. The reaction mixture was completed with 213 kg DCM and cooled to ⁇ 50° C. 107 kg 2-chloro-2-methylbutane in 107 kg DCM were added at ⁇ 50° C., although a temperature of ⁇ 60 to ⁇ 45° C. is acceptable, and stirred for 2.5 hours.
- Extractions using slightly acidic water (water and diluted HCl) were performed, followed by a further extraction with a solution of Na 3 PO 4 in water.
- a subsequent extraction was conducted using NaOH diluted in water to a pH ⁇ 13.
- pH ⁇ 13 At a lower pH value there is incomplete HCl removal, leading to distillation problems.
- Two washes were performed with water.
- the solvent was distilled off.
- the distillation step is necessary to purify Amorolfine Base.
- AMF base Apart from FPM, all impurities present in AMF base are removed firstly by the salification of AMF base into AMF HCl and secondly by one crystallization step from ethanol.
- the temperature raises by around 35° C. This exotherm is used to warm the batch. After the addition of HCl the temperature is raised to a level that ensures that the reaction mixture is in solution.
- the final temperature of ⁇ 20 to ⁇ 15° C. is important to obtain an optimum yield.
- Ethanol is the preferred solvent.
- the Amorolfine HCl is dissolved in hot ethanol and this solution is filtered to remove foreign matter. The filtrate is then cooled to ⁇ 15 to ⁇ 20° C. to get the optimum yield of crystallization. After centrifugation, the crystals are washed with an appropriate amount of ethanol.
- the Amorolfine HCl is stable up to 150° C. Drying conditions of 60° C. in a vacuum are used and do not 25 produce any problems with the residual solvent.
- the reactor was charged with 317 kg AMF and 640 kg ethanol. 38 kg HCl gas was added at 10-65° C. The reaction mixture was then heated to 60° C., followed by cooling to ⁇ 15 to ⁇ 20° C. The mixture was stored for 30 minutes to 2 hours.
- the Amorolfine HCl was centrifuged and washed with 210 kg of ethanol.
- the hot solution was filtered and the filter rinsed. with 15 kg hot ethanol.
- the filtrate was then cooled to ⁇ 15 to ⁇ 20° C. and stored for 30 minutes to 2 hours.
- the crystallized Amorolfine HCl was centrifuged and washed with 210 kg of ethanol.
- the mixture was then dried at a temperature of 60° C. under vacuum ( ⁇ 100 mbar).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
- This application is a divisional application of application Ser. No. 12/010,635, filed Jan. 28, 2008, which is a continuation of PCT/IB 2006/003362, filed Jul. 27, 2006 and designating the United States (published in the English language on Feb. 1, 2007 as WO 2007/012984 A2), which in turn claims priority under 35 U.S.C. §119 of EP 05291611.1, filed Jul. 28, 2005, each hereby expressly incorporated by reference in its entirety and each assigned to the assignee hereof.
- 1. Technical Field of the Invention
- The present invention relates to an improved process of producing bepromoline hydrochloride (bepromoline HCl), which is an intermediate used in the production of Amorolfine (AMF) hydrochloride (Amorolfine HCl).
- Amorolfine HCl is an active pharmaceutical ingredient (API) formulated into topical anti-mycotic (anti-fungal) compositions.
- 2. Description of Background and/or Related and/or Prior Art
- French Patent No 2,463,767 describes methods of producing Amorolfine HCl and intermediates for such production. In particular, a method for the production of bepromoline base of formula (Ia):
- is described, this method involving the step of reacting a compound of the formula (III):
- with a compound of the formula (IV):
- such that they undergo catalytic hydrogenation to produce bepromoline base. The suggested catalysts are those generally employed for hydrogenation, with specific mention of platinum, palladium, palladiumcarbon or Raney nickel catalysts. No indication is made of the pH of the hydrogenation conditions.
- Need continues to exist for improved processes for the production of Amorolfine salts, for example Amorolfine HCl, notably through an improvement in the production of its intermediates, such as bepromoline or a salt of bepromoline as, for example, bepromoline HCl.
- As employed herein, the term “bepromoline base” refers to the compound of formula (Ia), the term “bepromoline HCl” refers to the compound of formula (Ib), and the term “Amorolfine HCl” (AMF HCl) refers to the compound of formula (II):
- The present invention relates to an improved process for producing bepromoline HCl, an intermediate in the production of AMF HCl.
- According to a first embodiment of the invention, there is provided a process of preparing bepromoline base, which is a compound of formula (Ia):
- said process comprising:
(i) contacting a compound of formula (III): - with a compound of formula (IV):
- in the presence of a palladium catalyst, methanol and hydrogen gas, wherein (ii), once the consumption of hydrogen gas has ceased, acetic acid is added.
- This acetic acid addition (step (ii)) is for the reduction of the C═N double bond under hydrogen pressure.
- More preferably, step (i) is conducted under basic conditions and acetic acid added once the consumption of hydrogen gas has ceased.
- The reduction under hydrogen pressure of the C═C double bond is better conducted under basic conditions (step (i)), and once the consumption of hydrogen gas has ceased, the reduction under hydrogen pressure of the C═N double bond is better conducted under acetic conditions (step (ii)).
- Consequently, a preferred process according to the invention is a process of preparing bepromoline base, which is a compound of formula (Ia):
- said process comprising:
(i) contacting a compound of formula (III): - with a compound of formula (IV):
- in the presence of a palladium catalyst, methanol and hydrogen gas, wherein step (i) is conducted under basic conditions, and (ii), once the consumption of hydrogen gas has ceased, acetic acid is added.
- Compounds of formulae (III) and (IV) are termed herein “α-methylcinnamaldehyde” and “cis-2,6-dimethyl morpholine” (DMM), respectively.
- In one embodiment, the palladium catalyst comprises palladium precipitated onto carbon.
- Typically, the basic conditions are provided by potassium hydroxide, although other alkalis can also be used. It has been found that the inclusion of 1.5 to 2.0 mol % potassium hydroxide, typically about 1.8 mol % potassium hydroxide, is sufficient.
- Generally, the compounds of formulae (III) and (IV) are added in approximately equimolar proportions.
- According to a second embodiment of the present invention, there is provided a process for preparing a compound of formula (Ib):
- said process comprising a process described above for the first embodiment of the invention followed by the following step: (iii) contacting the compound of formula (Ia) with toluene and HCl gas to produce a compound of formula (Ib).
- In one embodiment, the toluene and HCl gas are added at a temperature of up to 50° C.
- In another embodiment, the process of preparing a compound of formula (Ib) includes one or more of the following steps:
- (a) purifying the compound of formula (Ia);
- (b) adding fresh toluene and HCl gas;
- (c) adjusting the pH to 3 to 4;
- (d) cooling to 0 to 5° C.;
- (e) stirring for at least 1 hour; and
- (f) isolating the end product of formula (Ib).
- In another embodiment, step (a) entails:
- (a1) filtering and washing the catalyst with methanol and water;
- (a2) removing any used methanol;
- (a3) adding toluene and extracting inorganic components using water; and
- (a4) removing used toluene and unreacted DMM.
- According to the present invention, the solubilization of the compound of formula (Ia) in toluene followed by acidification with hydrochloric acid are particularly useful, because this step avoids distillation of the compound of formula (Ia), which is long-time consuming. Moreover, the solid hydrochloride salt of formula (Ib) obtained in toluene is easier to handle than the liquid compound of formula (Ia) and can be directly employed in the following reaction.
- According to a third embodiment of the present invention, there is provided a process of preparing a compound of formula (V):
- said process comprising a process described above for any of the first, or second embodiment of the present invention.
- Compounds of formula (V) are termed herein “Amorolfine base” (RMF base).
- For example, in order to obtain Amorolfine base, bepromoline HCl (compound (Ib)) can be contacted with, for example, FeCl3, and then added to 2-chloro-2-methylbutane.
- For example, in order to obtain Amorolfine base, bepromoline base (compound (Ia)) can be converted to bepromoline HCl by a salification step, and then submitted to the same reactions as herein above described (contact with for example FeCl3, and then addition to 2-chloro-2-methylbutane).
- Typically, the process of the third embodiment further includes the step of reacting a compound of formula (Ib) with 2-chloro-2-methylbutane in the presence of FeCl3 as Friedel-Crafts catalyst.
- The Friedel-Crafts catalyst will usually be embodiment in a suitable solvent, for example dichloromethane (DCM).
- Typically, the compound of formula (Ib) is contacted with the Friedel-Crafts catalyst at room temperature.
- Usually, the 2-chloro-2-methylbutane is added to the compound of formula (Ib) at a temperature of −40° C. to −60° C., for example −50° C.
- According to a fourth embodiment of the present invention, there is provided a process for preparing a compound of formula (II) (AMF HCl), said process comprising the process of any of first, second, or third embodiments of the invention.
- In one embodiment, the process for preparing a compound of formula (II) further comprises the step of crystallizing AMF HCl from addition of HCl to a solution of AMF base in ethanol.
- Typical and usual features of each embodiment of the invention are as for each of the other embodiments of the invention mutatis mutandis.
- Finally, the present invention features the compound of formula (Ib) (bepromoline HCl):
- as such, which is produced according to the process as described in the second embodiment of the invention.
- The present invention also features the compound of formula (Ia) (bepromoline base) or to compound of formula (Ib) (bepromoline HCl), each of these compounds having a purity degree superior or equal to 99.5%.
- Throughout the specification, unless the context demands otherwise, the terms “comprise” or “include”, or variations such as “comprising” and “including” will be understood to imply the inclusion of a stated feature, or group of features, but not to the exclusion of any other feature, or group of features.
- In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that same are intended only as illustrative and in nowise limitative. In said examples to follow, all parts and percentages are given by weight, unless otherwise indicated.
- a) General Considerations:
- A mixture of one part of α-methyl-cinnamaldehyde to one part of cis-2,6-dimethyl-morpholine (DMM) is hydrogenated in methanol in the presence of catalytic amount of palladium on carbon, optionally under basic conditions until the uptake of H2 gas ceases, this indicating completion of the reduction of the C═C double bond. Acetic acid is then added for the reduction of the C═N double bond under hydrogen pressure; the C═N double bond is formed between the aldehyde and the amino moiety of the two reactants, α-methyl-cinnamaldehyde and DMM, respectively.
- The catalyst is then filtered off and the methanol is removed by distillation. Toluene is added and the inorganic components are removed by washing with water. Toluene and unreacted DMM are distilled off. Then fresh toluene and HCl gas are added and the pH is adjusted to 3-4. The bepromoline HCl is centrifuged and dried.
- Schematic of Production of Bepromoline HCl:
- Provision of Basic Conditions:
- Basic conditions were provided by KOH, which is used to neutralize the acidic components present in the α-methyl-cinnamaldehyde. The absence of traces of acid improved the kinetics of the reaction. The reduction of the aldehyde function to the corresponding alcohol is avoided by addition of KOH.
- Solvent:
- Methanol may be substituted by toluene to avoid the later solvent exchange step.
- Temperature of Hydrogenation:
- 40° C. is the optimum temperature for both hydrogenation steps. However, the temperature may typically be set at no more than 45° C., preferably between 30° C. and 45° C.
- Acetic Acid:
- The reduction for the C═N double bond formed between the aldehyde and the amino function of the two components is conducted under hydrogen pressure in acidic conditions after the addition of acetic acid.
- A molar ratio of acetic acid to KOH is around 1.3 (±10%).
- The acetic acid is typically added at a temperature range of between 40° C. to 45° C., and no more than 45° C.
- Toluene Exchange:
- The toluene is advantageously added to facilitate the phase separations and the distillation step of the unreacted DMM, thus improving the purity of bepromoline.
- Bepromoline HCl Purity:
- The trans isomers (VI) and (VII) of bepromoline, coming from trans isomers presents as byproducts in the 2,6-dimethyl morpholine starting material, are partially eliminated during the crystallization of bepromoline HCl.
- The purity of the bepromoline HCl (cis isomer) is superior or equal to 99.5%.
- Stability Temperature:
- The product is stable up to 150° C.
- b) Synthesis: (Weights are given for 1 kmol α-methyl-cinnamaldehyde).
- A reactor was charged with 146 kg a-methyl-cinnamaldehyde, 115 kg cis-2,6-dimethyl-morpholine, 2.1 kg 50% KOH, 278 kg methanol and 5.8 kg of a palladium/carbon catalyst and then filled with hydrogen at 15-25° C.
- The hydrogenation was then conducted at a pressure of ˜2 bar and 35-45° C. until H2 consumption ceased.
- 1.5 kg acetic acid was then added, and the hydrogenation was re-commenced. The hydrogenation was conducted at a pressure of ˜2 bar and at a temperature of 40-45° C. until no further H2 was consumed.
- The reaction mixture was filtered and the catalyst washed with methanol and water.
- The solvents were distilled off at a temperature of up to 95° C. under vacuum.
- Two extractions were performed using toluene and water. The waste water was drained off.
- The solvent was then distilled off under vacuum.
- The reactor was charged with 904 kg toluene and 33 kg HCl gas at a temperature of up to 50° C. Then the pH was adjusted to 3-4. The reaction mixture was cooled and then stored sufficiently to reached complete crystallization.
- The mixture was centrifuged and washed with cold (0-5° C.) toluene. A second crop of Bepromoline HCl was isolated from the mother liquor.
- The process yielded 287 kg wet bepromoline HCl, which was then dried at 60° C. under vacuum. After drying, the first crop of Bepromoline HCl was 227 kg and the second 18 kg. This corresponds to a yield of 87% (80% for the first crop Bepromoline HCl and 7% for the second crop).
- a) General Considerations:
- 1 part bepromoline HCl is treated with 1.3 parts FeCl3±5% in dichloromethane at room temperature. The resulting slurry is cooled to approximately −50° C., whereupon 1 to 1.1 parts of 2-chloro-2-methylbutane is added.
- After an appropriate reaction time of around 2.5 hours, the reaction mixture is poured onto an ice-water mixture. The organic phase is separated and washed with acidic water, and then with sodium phosphate solution and with sodium hydroxide solution. After a stripping with toluene, extractions with water are performed. The solvent is then removed. Then the residue is distilled.
- Schematic of Production of Amorolfine Base:
- Reaction Temperature for the addition of FeCl3 to Bepromoline HCl:
- The addition of FeCl3 to Bepromoline HCl takes place at room temperature. At lower temperatures the subsequent Friedel-Crafts alkylation fails partially or completely (Table 1).
-
TABLE 1 Bepromoline assay in the Temperature (° C.) crude Amorolfine base (%) 20-30 8-14 0 14 −20 100 - Friedel-Crafts Catalysts:
- A suitable molar ratio of FeCl3 to bepromoline is 1:2 to 1:5 equivalents of catalyst. 1.3 equivalents of FeCl3 are preferred.
- Reaction Temperature for Friedel-Crafts Alkylation:
- To decrease the Fenpropimorph (FPM) byproduct, the reaction is conducted at low temperature, preferably −50° C. (see Table 2):
-
-
TABLE 2 Temperature (° C.) FPM (%) −52 to −49 0.14-0.25 −40 1.7 −35 2.0 −20 2.7 - Fenpropimorph (FPM) is a problematic byproduct as it is difficult to remove from the end product.
- Ratio of Bepromoline HCl to 2-chloro-2-methylbutane:
- Batches were performed with 10% excess 2-chloro-2-methylbutane and at a 1:1 ratio. The FPM assay is lower for the 1:1 ratio and thus this proportion is preferred.
- Phosphate and Alkaline Extraction:
- The Amorolfine HCl (which is in the DCM) is converted to the free base during these extractions. Phosphate was used to remove traces of Fe.
- Solvent Exchange:
- Advantages result if the solvents are exchanged (i.e., toluene in place of DCM): the volume is reduced and the waste-water is contaminated with less chlorinated solvent.
- Toluene-water Extraction:
- These extractions are necessary to get the appropriate quality for the subsequent distillation. If these extractions are omitted, the Amorolfine base slightly decomposes at 180° C. The distillation becomes very sluggish and fumes are formed. The vacuum distillation is then not possible at plant scale.
- The yield was approximately 90% of crude Amorolfine base.
- b) Synthesis:(weights are given for 1 kmol bepromoline HCl).
- The reactor was charged with 212 kg FeCl3 and 757 kg DCM. 284 kg bepromoline HCl in 946 kg DCM were added to the reactor at 20-30° C. The reaction mixture was completed with 213 kg DCM and cooled to −50° C. 107 kg 2-chloro-2-methylbutane in 107 kg DCM were added at −50° C., although a temperature of −60 to −45° C. is acceptable, and stirred for 2.5 hours.
- Hydrolysis was performed using 255 kg ice and 785 kg water.
- Phase separation was then performed.
- Extractions using slightly acidic water (water and diluted HCl) were performed, followed by a further extraction with a solution of Na3PO4 in water. A subsequent extraction was conducted using NaOH diluted in water to a pH≧13. At a lower pH value there is incomplete HCl removal, leading to distillation problems. Two washes were performed with water.
- The solvent was distilled off.
- Toluene was added and water extractions were performed. Finally the solvent was distilled off under vacuum.
- This yielded 283 kg crude AMF (approximately 90% AMF base crude)
- a) General Considerations:
- The distillation step is necessary to purify Amorolfine Base.
- Schematic of the Distillation Process:
- b) Distillation:
- 283 kg of crude Amorolfine base are distilled at 141°-144° C. under reduced pressure (typically 0.14-0.15 mbar). The fractions are combined in such a way that the impurity profile of the combined material is within the desired specification.
- After distillation, 190 kg AMF base were produced (approximately 67% AMF base distilled).
- a) General Considerations:
- i) Purpose: The goal of this stage is to ensure that sufficient impurities are properly removed with the formation of the Amorolfine HCl and only one crystallization step with ethanol being used.
- ii) production of Amorolfine HCl with Amorolfine base (salification step): HCl gas is added to a solution of Amorolfine base in two parts of ethanol until the pH reaches 1.5 to 3. The Amorolfine HCl crystallizes at around 45° C. The slurry is cooled to no less than −15° C. (which should take no less than 2 hours). The crude Amorolfine HCl is isolated by centrifugation and washed with cold ethanol. The crude Amorolfine HCl is then recrystallized from two parts of ethanol.
- Schematic of the Process:
- Amounts of byproducts in the Amorolfine base:
- Apart from FPM, all impurities present in AMF base are removed firstly by the salification of AMF base into AMF HCl and secondly by one crystallization step from ethanol.
- The data given in Table 3 were taken from different crystallization experiments.
-
TABLE 3 Bepromoline (%) FPM (%) Trans-isomers (%) AMF base 5 0.25 0.5 AMF HCl crude 0.3 0.25 0.3 AMF HCl <0.1 0.25 <0.2 Required spec. <0.2 <0.3 <0.2 - Reaction Temperature:
- During the addition of the HCl gas, the temperature raises by around 35° C. This exotherm is used to warm the batch. After the addition of HCl the temperature is raised to a level that ensures that the reaction mixture is in solution.
- The final temperature of −20 to −15° C. is important to obtain an optimum yield.
- Recrystallization of the Amorolfine HCl:
- Ethanol is the preferred solvent. The Amorolfine HCl is dissolved in hot ethanol and this solution is filtered to remove foreign matter. The filtrate is then cooled to −15 to −20° C. to get the optimum yield of crystallization. After centrifugation, the crystals are washed with an appropriate amount of ethanol.
- Drying:
- The Amorolfine HCl is stable up to 150° C. Drying conditions of 60° C. in a vacuum are used and do not 25 produce any problems with the residual solvent.
- b) Synthesis: (Weights are given for 1 kmol AMF base).
- The reactor was charged with 317 kg AMF and 640 kg ethanol. 38 kg HCl gas was added at 10-65° C. The reaction mixture was then heated to 60° C., followed by cooling to −15 to −20° C. The mixture was stored for 30 minutes to 2 hours.
- The Amorolfine HCl was centrifuged and washed with 210 kg of ethanol.
- 2 parts ethanol were used to dissolve the Amorolfine HCl at 70-80° C.
- The hot solution was filtered and the filter rinsed. with 15 kg hot ethanol. The filtrate was then cooled to −15 to −20° C. and stored for 30 minutes to 2 hours.
- The crystallized Amorolfine HCl was centrifuged and washed with 210 kg of ethanol.
- The mixture was then dried at a temperature of 60° C. under vacuum (<100 mbar).
- This yielded 271 kg AMF HCl. The yield was approximately 77%.
- Each patent, patent application, publication, text and literature article/report cited or indicated herein is hereby expressly incorporated by reference in its entirety.
- While the invention has been described in terms of various specific and preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions, omissions, and changes may be made without departing from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims, including equivalents thereof.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/858,273 US8242268B2 (en) | 2005-07-28 | 2010-08-17 | Production of bepromoline |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05291611.1 | 2005-07-28 | ||
EP05291611 | 2005-07-28 | ||
EP05291611A EP1749826A1 (en) | 2005-07-28 | 2005-07-28 | Process of producing bepromoline |
PCT/IB2006/003362 WO2007012984A2 (en) | 2005-07-28 | 2006-07-27 | Process of producing bepromoline |
US12/010,635 US7795425B2 (en) | 2005-07-28 | 2008-01-28 | Production of bepromoline |
US12/858,273 US8242268B2 (en) | 2005-07-28 | 2010-08-17 | Production of bepromoline |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/010,635 Division US7795425B2 (en) | 2005-07-28 | 2008-01-28 | Production of bepromoline |
Publications (2)
Publication Number | Publication Date |
---|---|
US20100311967A1 true US20100311967A1 (en) | 2010-12-09 |
US8242268B2 US8242268B2 (en) | 2012-08-14 |
Family
ID=35064906
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/010,635 Active 2027-06-22 US7795425B2 (en) | 2005-07-28 | 2008-01-28 | Production of bepromoline |
US12/858,273 Active 2026-10-09 US8242268B2 (en) | 2005-07-28 | 2010-08-17 | Production of bepromoline |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/010,635 Active 2027-06-22 US7795425B2 (en) | 2005-07-28 | 2008-01-28 | Production of bepromoline |
Country Status (12)
Country | Link |
---|---|
US (2) | US7795425B2 (en) |
EP (2) | EP1749826A1 (en) |
AR (1) | AR054873A1 (en) |
BR (1) | BRPI0613307B8 (en) |
CA (1) | CA2616160C (en) |
CY (1) | CY1113779T1 (en) |
DK (1) | DK1912961T3 (en) |
ES (1) | ES2399245T3 (en) |
PL (1) | PL1912961T3 (en) |
PT (1) | PT1912961E (en) |
SI (1) | SI1912961T1 (en) |
WO (1) | WO2007012984A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1749826A1 (en) * | 2005-07-28 | 2007-02-07 | Galderma S.A. | Process of producing bepromoline |
EP1935889A1 (en) * | 2006-12-21 | 2008-06-25 | Galderma S.A. | Process of producing amorolfine |
ITFI20090032A1 (en) * | 2009-02-20 | 2010-08-21 | Synteco S P A Prodotti Di Sintesi Per L Ind | INDUSTRIAL PRODUCTION PROCESS OF CHLORIDATED AMOROLFIN |
WO2011066735A1 (en) * | 2009-12-01 | 2011-06-09 | Zhejiang Hisoar Pharmaceutical Co., Ltd | An Amorolfine HCl Crystal and the Preparation thereof |
CN102887872B (en) * | 2011-12-30 | 2015-06-24 | 浙江海翔药业股份有限公司 | Method for preparing amorolfine hydrochloride |
CN109232458A (en) * | 2018-06-15 | 2019-01-18 | 南通常佑药业科技有限公司 | A kind of preparation method of chirality morpholinium compound |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3046280A (en) * | 1955-11-24 | 1962-07-24 | Philips Corp | Primary, secondary and tertiary amines having a spasmolytic effect and method of producing these compounds |
US4202894A (en) * | 1976-11-22 | 1980-05-13 | Hoffmann-La Roche Inc. | Piperidines morpholines, etc., and fungicidal compositions thereof |
US4283534A (en) * | 1979-04-11 | 1981-08-11 | Basf Aktiengesellschaft | Reductive alkylation of nitrogen heterocycles |
US7795425B2 (en) * | 2005-07-28 | 2010-09-14 | Galderma S.A. | Production of bepromoline |
US8049007B2 (en) * | 2006-12-21 | 2011-11-01 | Galderma S.A. | Preparation of amorolfine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2656747C2 (en) * | 1976-12-15 | 1984-07-05 | Basf Ag, 6700 Ludwigshafen | Morpholine derivatives |
ZW15780A1 (en) | 1979-08-17 | 1981-03-18 | Hoffmann La Roche | Heterocyclic compounds |
-
2005
- 2005-07-28 EP EP05291611A patent/EP1749826A1/en not_active Withdrawn
-
2006
- 2006-07-27 CA CA2616160A patent/CA2616160C/en not_active Expired - Fee Related
- 2006-07-27 AR ARP060103245A patent/AR054873A1/en not_active Application Discontinuation
- 2006-07-27 PT PT68209808T patent/PT1912961E/en unknown
- 2006-07-27 ES ES06820980T patent/ES2399245T3/en active Active
- 2006-07-27 EP EP06820980A patent/EP1912961B1/en active Active
- 2006-07-27 SI SI200631523T patent/SI1912961T1/en unknown
- 2006-07-27 BR BRPI0613307A patent/BRPI0613307B8/en active IP Right Grant
- 2006-07-27 PL PL06820980T patent/PL1912961T3/en unknown
- 2006-07-27 WO PCT/IB2006/003362 patent/WO2007012984A2/en active Application Filing
- 2006-07-27 DK DK06820980.8T patent/DK1912961T3/en active
-
2008
- 2008-01-28 US US12/010,635 patent/US7795425B2/en active Active
-
2010
- 2010-08-17 US US12/858,273 patent/US8242268B2/en active Active
-
2013
- 2013-03-05 CY CY20131100207T patent/CY1113779T1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3046280A (en) * | 1955-11-24 | 1962-07-24 | Philips Corp | Primary, secondary and tertiary amines having a spasmolytic effect and method of producing these compounds |
US4202894A (en) * | 1976-11-22 | 1980-05-13 | Hoffmann-La Roche Inc. | Piperidines morpholines, etc., and fungicidal compositions thereof |
US4283534A (en) * | 1979-04-11 | 1981-08-11 | Basf Aktiengesellschaft | Reductive alkylation of nitrogen heterocycles |
US7795425B2 (en) * | 2005-07-28 | 2010-09-14 | Galderma S.A. | Production of bepromoline |
US8049007B2 (en) * | 2006-12-21 | 2011-11-01 | Galderma S.A. | Preparation of amorolfine |
Also Published As
Publication number | Publication date |
---|---|
EP1749826A1 (en) | 2007-02-07 |
BRPI0613307B1 (en) | 2021-04-06 |
CA2616160C (en) | 2014-02-11 |
AR054873A1 (en) | 2007-07-25 |
BRPI0613307B8 (en) | 2021-05-25 |
SI1912961T1 (en) | 2013-04-30 |
US8242268B2 (en) | 2012-08-14 |
WO2007012984A2 (en) | 2007-02-01 |
US7795425B2 (en) | 2010-09-14 |
WO2007012984A3 (en) | 2007-06-14 |
CY1113779T1 (en) | 2016-07-27 |
DK1912961T3 (en) | 2013-02-11 |
BRPI0613307A2 (en) | 2010-12-28 |
EP1912961B1 (en) | 2012-12-05 |
ES2399245T3 (en) | 2013-03-26 |
CA2616160A1 (en) | 2007-02-01 |
PL1912961T3 (en) | 2013-04-30 |
EP1912961A2 (en) | 2008-04-23 |
US20080269483A1 (en) | 2008-10-30 |
PT1912961E (en) | 2013-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8242268B2 (en) | Production of bepromoline | |
CA2601149C (en) | Process of producing amorolfine | |
US8049007B2 (en) | Preparation of amorolfine | |
KR101083147B1 (en) | Process for iohexol manufacture | |
US20090156802A1 (en) | Quetiapine Hemifumarate Purification by Crystallization | |
US6399829B1 (en) | Synthesis and purification of (r*,r*)-2-[ (dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride | |
US20220064102A1 (en) | Process for preparation of highly pure fingolimod hydrochloride | |
US6262308B1 (en) | Process for the preparation of racemic sertraline | |
JP2017505302A (en) | Improved process for producing trazodone and its hydrochloride | |
US6307103B1 (en) | Process for the preparation of 1,1,1-trifluoro-2-aminoalkanes | |
EP2279998B1 (en) | Synthesis of iodixanol in propyleneglycol | |
US7462718B2 (en) | Process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate and high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate | |
EP2277852B1 (en) | Synthesis of iodixanol in water | |
US20040242879A1 (en) | Process for preparing 1-methyl-3-phenylpiperazine using a novel intermediate | |
EP1044960B1 (en) | Process for the preparation of 1,1,1-trifluoro-2-aminoalkanes | |
KR100342919B1 (en) | A preparation and purification for trans isomer of tramadol hydrochloride | |
US20050176963A1 (en) | Method of producing biperiden I | |
JP2008308458A (en) | Production method of pyridinecarbonyl compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
AS | Assignment |
Owner name: GALDERMA HOLDING SA, SWITZERLAND Free format text: CHANGE OF NAME;ASSIGNOR:NESTLE SKIN HEALTH S.A.;REEL/FRAME:057698/0356 Effective date: 20200129 Owner name: NESTLE SKIN HEALTH S.A., SWITZERLAND Free format text: ASSET TRANSFER AGREEMENT;ASSIGNOR:GALDERMA S.A.;REEL/FRAME:057698/0295 Effective date: 20160210 |
|
AS | Assignment |
Owner name: GALDERMA HOLDING SA, SWITZERLAND Free format text: CHANGE OF ADDRESS;ASSIGNOR:GALDERMA HOLDING SA;REEL/FRAME:060541/0374 Effective date: 20220217 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |